Skip to content
value.today
Sanara MedTech Inc. logo

Sanara MedTech Inc.

Formerly Wound Management Technologies, Inc.

Sanara MedTech Inc. is listed today as Sanara MedTech Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Sanara MedTech Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2023$3 MPrivate placement after listing$2 to $10 million

Sanara MedTech Inc.: Private sale, Aug 2023

Investors in this round

1 investor had bought by the notice of Aug 11, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Sanara MedTech Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Michael D. McNeil · Executive Officer · Chief Financial Officer
  • Zachary B. Fleming · Executive Officer · Chief Executive Officer
  • Ann Beal Salamone · Director
  • Eric D. Major · Director
  • Eric D. Tanzberger · Director
  • James W. Stuckert · Director
  • Robert A. DeSutter · Director
  • Ronald T. Nixon · Director · Executive Chairman
  • Roszell A. Mack III · Director
  • Sara N. Ortwein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Consists of shares of common stock of the Issuer issued as partial consideration in an asset purchase, which share amounts were based upon the 20-day historical average closing price prior to closing.”

Signed by Michael D. McNeil, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 11, 2023. Read the notice at the SEC.

equitySEC
Jul 2022$16 MPrivate placement after listing$10 to $50 million

Sanara MedTech Inc.: Private sale, Jul 2022

Investors in this round

1 investor had bought by the notice of Jul 14, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Sanara MedTech Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Christopher A. Morrison · Executive Officer · President, Telehealth Services
  • Michael D. McNeil · Executive Officer · Chief Financial Officer
  • Rebecca E. McMahon · Executive Officer · President, Research and Development
  • Shawn M. Bowman · Executive Officer · President, Strategic Partnerships
  • Zachary B. Fleming · Executive Officer · Chief Executive Officer
  • Ann Beal Salamone · Director
  • Eric D. Tanzberger · Director
  • James W. Stuckert · Director
  • Kenneth E. Thorpe · Director
  • Robert A. DeSutter · Director
  • Ronald T. Nixon · Director · Executive Chairman
  • Roszell A. Mack III · Director
  • Sara N. Ortwein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes maximum potential earnout, which is payable in cash or equity at the Issuer's election.”

Signed by Michael D. McNeil, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 14, 2022. Read the notice at the SEC.

equitySEC
Apr 2022$15 MPrivate placement after listing$10 to $50 million

Sanara MedTech Inc.: Private sale, Apr 2022

Investors in this round

46 investors had bought by the notice of Jun 2, 2022: 46 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Sanara MedTech Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • Christopher A. Morrison · Executive Officer · President, Telehealth Services
  • Michael D. McNeil · Executive Officer · Chief Financial Officer
  • Rebecca E. McMahon · Executive Officer · President, Research and Development
  • Shawn M. Bowman · Executive Officer · President, Strategic Partnerships
  • Zachary B. Fleming · Executive Officer · Chief Executive Officer
  • Ann Beal Salamone · Director
  • Eric D. Tanzberger · Director
  • James W. Stuckert · Director
  • Kenneth E. Thorpe · Director
  • Robert A. DeSutter · Director
  • Ronald T. Nixon · Director
  • Roszell A. Mack III · Director
  • Sara N. Ortwein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amounts based upon 20-day historical average closing price prior to closing and includes maximum potential earnout, which is payable in cash or equity at the Issuer's election. Any non-accredited investors may only be paid in cash, not equity.”

Signed by Michael D. McNeil, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 2, 2022. Read the notice at the SEC.

equitySEC
Jan 2021$1 MPrivate placement after listingUnder $2 million

Sanara MedTech Inc.: Private sale, Jan 2021

Investors in this round

2 investors had bought by the notice of Jan 25, 2021: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Sanara MedTech Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Texas

People named in the notice

  • J. Michael Carmena · Director, Executive Officer · Vice Chairman and Principal Executive Officer
  • Michael Michael McNeil · Executive Officer · Chief Financial Officer
  • Shawn Michael Bowman · Executive Officer · Co-Chief Operating Officer and President, Wound Care
  • Zachary Michael Fleming · Executive Officer · Co-Chief Operating Officer and President, Surgical
  • Ann Michael Salamone · Director · Director
  • James Michael Stuckert · Director · Director
  • Kenneth Michael Thorpe · Director · Director
  • Robert Michael DeSutter · Director
  • Ronald Michael Nixon · Director
  • Sara Michael Ortwein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Total Offering Amount and Total Amount Sold are based upon the closing price of the Issuer's common stock on The Nasdaq Capital Market on 1/14/2021.”

Signed by Michael D. McNeil, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 25, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Sanara MedTech Inc., its revenue in fiscal 2025 came from these product and service lines: Soft Tissue Repair Products $91.35 million (89%), Bone Fusion Products $11.77 million (11%).

    Annual report (SEC XBRL) · Dec 2025

  • Sanara MedTech Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2023).

    SEC Form D · Aug 2023

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Aug 2023

Products and services#

No products or services of Sanara MedTech Inc. are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Sanara MedTech Inc.
InvestorKindAmountRoundRoleSource
Catalyst Rochal, LLCOthernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2019)SEC Form 3
CGI Cellerate RX, LLCOthernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Darren StinePersonnot statednot statedHeld Series D preferred stock (Form 3, 2014)SEC Form 3
James W. StuckertPersonnot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
John Christopher SiedhoffPersonnot statednot statedHeld Series D preferred stock, director (Form 3, 2017)SEC Form 3
S. Oden Howell Jr.Personnot statednot statedHeld Series C preferred stock, 10% owner, director (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Sanara MedTech Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Sanara MedTech Inc.
NameRoleNamed in
Michael D. McNeilChief Financial OfficerAug 2023
Zachary B. FlemingChief Executive OfficerAug 2023
Christopher A. MorrisonPresident, Telehealth ServicesJul 2022
Rebecca E. McMahonPresident, Research and DevelopmentJul 2022
Shawn M. BowmanPresident, Strategic PartnershipsJul 2022
J. Michael CarmenaVice Chairman and Principal Executive OfficerJan 2021
Michael Michael McNeilChief Financial OfficerJan 2021
Shawn Michael BowmanCo-Chief Operating Officer and President, Wound CareJan 2021
Zachary Michael FlemingCo-Chief Operating Officer and President, SurgicalJan 2021
Ann Beal SalamoneDirectorAug 2023
Eric D. MajorDirectorAug 2023
Eric D. TanzbergerDirectorAug 2023
James W. StuckertDirectorAug 2023
Robert A. DeSutterDirectorAug 2023
Ronald T. NixonExecutive ChairmanAug 2023
Roszell A. Mack IIIDirectorAug 2023
Sara N. OrtweinDirectorAug 2023
Kenneth E. ThorpeDirectorJul 2022
Ann Michael SalamoneDirectorJan 2021
J. Michael CarmenaVice Chairman and Principal Executive OfficerJan 2021
James Michael StuckertDirectorJan 2021
Kenneth Michael ThorpeDirectorJan 2021
Robert Michael DeSutterDirectorJan 2021
Ronald Michael NixonDirectorJan 2021
Sara Michael OrtweinDirectorJan 2021

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.